company background image
NEO

NeoGenomicsNasdaqCM:NEO Stock Report

Market Cap

US$5.8b

7D

-0.1%

1Y

29.8%

Updated

27 Sep, 2021

Data

Company Financials +
NEO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance2/6
Financial Health2/6
Dividends0/6

NEO Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia.

NeoGenomics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NeoGenomics
Historical stock prices
Current Share PriceUS$46.94
52 Week HighUS$35.74
52 Week LowUS$61.57
Beta0.66
1 Month Change-3.20%
3 Month Change0.95%
1 Year Change29.81%
3 Year Change212.52%
5 Year Change481.30%
Change since IPO1,705.39%

Recent News & Updates

Shareholder Returns

NEOUS Life SciencesUS Market
7D-0.1%0.8%0.1%
1Y29.8%56.4%35.3%

Return vs Industry: NEO underperformed the US Life Sciences industry which returned 56.4% over the past year.

Return vs Market: NEO underperformed the US Market which returned 35.3% over the past year.

Price Volatility

Is NEO's price volatile compared to industry and market?
NEO volatility
NEO Beta0.66
Industry Beta0.97
Market Beta1

Stable Share Price: NEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: NEO's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20011,700Mark Mallonhttps://www.neogenomics.com

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.

NeoGenomics Fundamentals Summary

How do NeoGenomics's earnings and revenue compare to its market cap?
NEO fundamental statistics
Market CapUS$5.77b
Earnings (TTM)US$71.73m
Revenue (TTM)US$488.70m

80.5x

P/E Ratio

11.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NEO income statement (TTM)
RevenueUS$488.70m
Cost of RevenueUS$276.84m
Gross ProfitUS$211.86m
ExpensesUS$140.12m
EarningsUS$71.73m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.58
Gross Margin43.35%
Net Profit Margin14.68%
Debt/Equity Ratio46.5%

How did NEO perform over the long term?

See historical performance and comparison

Valuation

Is NeoGenomics undervalued compared to its fair value and its price relative to the market?

80.47x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NEO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NEO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NEO is poor value based on its PE Ratio (80.3x) compared to the US Life Sciences industry average (53.1x).

PE vs Market: NEO is poor value based on its PE Ratio (80.3x) compared to the US market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: NEO's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: NEO is good value based on its PB Ratio (5x) compared to the US Life Sciences industry average (6.1x).


Future Growth

How is NeoGenomics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

-81.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NEO's earnings are forecast to decline over the next 3 years (-81.8% per year).

Earnings vs Market: NEO's earnings are forecast to decline over the next 3 years (-81.8% per year).

High Growth Earnings: NEO's earnings are forecast to decline over the next 3 years.

Revenue vs Market: NEO's revenue (13.8% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: NEO's revenue (13.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NEO is forecast to be unprofitable in 3 years.


Past Performance

How has NeoGenomics performed over the past 5 years?

64.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NEO has a large one-off loss of $15.9M impacting its June 30 2021 financial results.

Growing Profit Margin: NEO became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: NEO has become profitable over the past 5 years, growing earnings by 64% per year.

Accelerating Growth: NEO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: NEO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (56.9%).


Return on Equity

High ROE: NEO's Return on Equity (6.2%) is considered low.


Financial Health

How is NeoGenomics's financial position?


Financial Position Analysis

Short Term Liabilities: NEO's short term assets ($721.8M) exceed its short term liabilities ($99.1M).

Long Term Liabilities: NEO's short term assets ($721.8M) exceed its long term liabilities ($648.8M).


Debt to Equity History and Analysis

Debt Level: NEO's debt to equity ratio (46.5%) is considered high.

Reducing Debt: NEO's debt to equity ratio has increased from 21.7% to 46.5% over the past 5 years.

Debt Coverage: NEO's debt is not well covered by operating cash flow (1.4%).

Interest Coverage: Insufficient data to determine if NEO's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is NeoGenomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NEO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NEO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Mark Mallon (58 yo)

0.42

Tenure

Mr. Mark W. Mallon serves as Chief Executive Officer and Director at NeoGenomics Laboratories, Inc. since April 19, 2021. He serves as Chief Executive Officer and Director at NeoGenomics, Inc. since April...


Leadership Team

Experienced Management: NEO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: NEO's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.4%.


Top Shareholders

Company Information

NeoGenomics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: NeoGenomics, Inc.
  • Ticker: NEO
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.772b
  • Shares outstanding: 122.97m
  • Website: https://www.neogenomics.com

Number of Employees


Location

  • NeoGenomics, Inc.
  • 12701 Commonwealth Drive
  • Suite 9
  • Fort Myers
  • Florida
  • 33913
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/27 23:00
End of Day Share Price2021/09/27 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.